EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SSY Group's enterprise value is HK$16,248 Mil.
SSY Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,804 Mil. Therefore, SSY Group's EV-to-EBITDA for today is 9.01.
The historical rank and industry rank for SSY Group's EV-to-EBITDA or its related term are showing as below:
HKSE:02005'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.72 Med: 12.23 Max: 25.43
Current: 9.01
During the past 13 years, the highest EV-to-EBITDA of SSY Group was 25.43. The lowest was 6.72. And the median was 12.23.
HKSE:02005's EV-to-EBITDA is ranked better than 73.2% of 709
companies
in the Drug Manufacturers industry
Industry Median: 14.88
vs HKSE:02005: 9.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-17), SSY Group's stock price is HK$4.84.
SSY Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.443. Therefore, SSY Group's PE Ratio for today is 10.93.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
SSY Group EV-to-EBITDA Historical Data
The historical data trend for SSY Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SSY Group's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SSY Group's EV-to-EBITDA falls into.
SSY Group EV-to-EBITDA Calculation
SSY Group's EV-to-EBITDA for today is calculated as:
SSY Group's current Enterprise Value is HK$16,248 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,804 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SSY Group's share price for today is HK$4.84.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.443.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of SSY Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02005 has been successfully added to your 